EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MCT4 blockade increases the efficacy of immune checkpoint blockade

Nathalie Babl iD, Sonja-Maria Decking, Florian Voll, Michael Althammer, Ada Sala-Hojman, Roberta Ferretti, Clarissa Korf, Christian Schmidl, Lisa Schmidleithner, Benedikt Nerb, Carina Matos, Gudrun E Koehl und 14 weitere

Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007349

DOI: 10.1136/jitc-2023-007349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.10.2023. Verfasst von Nathalie Babl und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck KGaA, Darmstadt, Germany, Leibniz Institute for Immunotherapy Regensburg, Else Kröner-Fresenius-Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Intratumoral lactate accumulation and acidosis impair T-cell function and antitumor immunity. Interestingly, expression of the lactate transporter monocarboxylate transporter (MCT) 4, but not MCT1, turned out to be prognostic for the survival of patients with rectal cancer, indicating that single MCT4 blockade might be a promising strategy to overcome glycolysis-related therapy resistance.

Methods

To determine whether blockade of MCT4 alone is sufficient to improve the efficacy of immune checkpoint blockade (ICB) therapy, we examined the effects of the selective MCT1 inhibitor AZD3965 and a novel MCT4 inhibitor in a colorectal carcinoma (CRC) tumor spheroid model co-cultured with blood leukocytes in vitro and the MC38 murine CRC model in vivo in combination with an antibody against programmed cell death ligand-1(PD-L1).

Results

Inhibition of MCT4 was sufficient to reduce lactate efflux in three-dimensional (3D) CRC spheroids but not in two-dimensional cell-cultures. Co-administration of the MCT4 inhibitor and ICB augmented immune cell infiltration, T-cell function and decreased CRC spheroid viability in a 3D co-culture model of human CRC spheroids with blood leukocytes. Accordingly, combination of MCT4 and ICB increased intratumoral pH, improved leukocyte infiltration and T-cell activation, delayed tumor growth, and prolonged survival in vivo. MCT1 inhibition exerted no further beneficial impact.

Conclusions

These findings demonstrate that single MCT4 inhibition represents a novel therapeutic approach to reverse lactic-acid driven immunosuppression and might be suitable to improve ICB efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsAnimalsHumansMiceCell Line, TumorGlycolysisLactic AcidMonocarboxylic Acid TransportersMuscle ProteinsPyrimidinonesThiophenes

Stichwörter der Autor:innen

Drug Therapy, CombinationImmune Checkpoint InhibitorsImmunologic SurveillanceLymphocytes, Tumor-InfiltratingMetabolismTumor Microenvironment

Substanzen

Immune Checkpoint InhibitorsLactic AcidMonocarboxylic Acid TransportersSLC16A4 protein, humanMuscle ProteinsSlc16a4 protein, mouseAZD3965PyrimidinonesThiophenes

Autor:innen und Institutionen

  • Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany.
  • Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Merck Healthcare KGaA, Darmstadt, Germany.
  • EMD Serono Research and Development Institute, Inc, Billerica, Massachusetts, USA, an affiliate of Merck KGaA.
  • Department of Surgery, University Hospital Regensburg, Regensburg, Germany.

ORCID-Profile: Nathalie Babl, Peter Siska

Förderung

  • Merck KGaA, Darmstadt, Germany
  • Leibniz Institute for Immunotherapy Regensburg
  • Else Kröner-Fresenius-Foundation

Zitieren

APA

Babl, N., Decking, S. M., Voll, F., Althammer, M., Sala-Hojman, A., Ferretti, R., Korf, C., Schmidl, C., Schmidleithner, L., Nerb, B., Matos, C., Koehl, G. E., Siska, P., Bruss, C., Kellermeier, F., Dettmer, K., Oefner, P. J., Wichland, M., Ugele, I., …, & Renner, K. (2023). MCT4 blockade increases the efficacy of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer, 11(10), e007349. https://doi.org/10.1136/jitc-2023-007349

Vancouver

Babl N, Decking SM, Voll F, Althammer M, Sala-Hojman A, Ferretti R, et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007349. doi:10.1136/jitc-2023-007349

BibTeX
@article{Babl2023,
  author = {Babl, Nathalie and Decking, Sonja-Maria and Voll, Florian and Althammer, Michael and Sala-Hojman, Ada and Ferretti, Roberta and Korf, Clarissa and Schmidl, Christian and Schmidleithner, Lisa and Nerb, Benedikt and Matos, Carina and Koehl, Gudrun E and Siska, Peter and Bruss, Christina and Kellermeier, Fabian and Dettmer, Katja and Oefner, Peter J and Wichland, Marvin and Ugele, Ines and Bohr, Christopher and Herr, Wolfgang and Ramaswamy, Shivapriya and Heinrich, Timo and Herhaus, Christian and Kreutz, Marina and Renner, Kathrin},
  title = {MCT4 blockade increases the efficacy of immune checkpoint blockade},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {e007349},
  doi = {10.1136/jitc-2023-007349}
}
Kostenlos starten →